Literature DB >> 15248231

Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia.

Mark H Wener1, Kathleen Hutchinson, Chihiro Morishima, David R Gretch.   

Abstract

OBJECTIVE: To determine if antibodies to cyclic citrullinated peptide (anti-CCP) are found in chronic hepatitis C virus (HCV) infection.
METHODS: Rheumatoid factor (RF) and anti-CCP were measured in sera from 50 patients with HCV infection but without cryoglobulinemia, sera from 29 patients with mixed cryoglobulinemia (including 13 with rheumatic symptoms and 5 with arthritis), and sera from 20 normal blood donors. Anti-CCP was measured by second-generation enzyme-linked immunosorbent assay (ELISA).
RESULTS: No sera with elevated anti-CCP were found in patients with HCV infection without cryoglobulinemia, and in that population, the maximum anti-CCP was 10 units, well below the positive cutoff of 20 units. Positive findings on RF testing >13 IU/ml were present in 22 (44%) of the HCV patients, with RF >50 IU/ml in 8 (16%) and a maximum RF of 526 IU/ml. Of the cryoglobulinemia patients, 22 (76%) had positive results on tests for RF, including 18 (62%) with RF >50 IU/ml and a maximum RF of 5,540 IU/ml. Two (6.9%) of the cryoglobulinemia patients had borderline-positive findings on tests for anti-CCP (25 units and 37 units), which were false-positive results caused by nonspecific binding in the ELISA. No association between the RF and the anti-CCP concentrations was found.
CONCLUSION: Whereas RF was frequent in patients with HCV infection with and without cryoglobulinemia, anti-CCP was not observed in patients with uncomplicated HCV infection. Borderline-positive anti-CCP results were observed infrequently in patients with mixed cryoglobulinemia and were caused by nonspecific binding to plastic. Measurement of anti-CCP may help in diagnosing RA in patients with chronic HCV infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15248231     DOI: 10.1002/art.20355

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  30 in total

1.  Second generation automated anti-CCP test better predicts the clinical diagnosis of rheumatoid arthritis.

Authors:  Mohamed Elrefaei; Kristie Boose; Martha McGee; Teresa K Tarrant; Feng-Chang Lin; Jason P Fine; John L Schmitz
Journal:  J Clin Immunol       Date:  2011-11-10       Impact factor: 8.317

2.  Anti-cyclic citrullinated peptide and rheumatoid factor in HIV positive patients.

Authors:  Zeljko Romic; Lovorka Derek; Vitomir Burek; Adriana Unic; Tihana Serdar; Domagoj Marijancevic; Jadranka Morovic-Vergles; Josko Mitrovic; Mladen Petrovecki
Journal:  Rheumatol Int       Date:  2010-05-27       Impact factor: 2.631

3.  Antibodies to mutated citrullinated vimentin in patients with chronic hepatitis C virus genotype IV infection-related arthropathy.

Authors:  M Zehairy; E Soliman; A Daghaidy
Journal:  Rheumatol Int       Date:  2011-11-09       Impact factor: 2.631

4.  Positive anti-cyclic citrullinated proteins and rheumatoid factor during active lung tuberculosis.

Authors:  O Elkayam; R Segal; M Lidgi; D Caspi
Journal:  Ann Rheum Dis       Date:  2005-12-16       Impact factor: 19.103

5.  Hepatitis C virus infection and its rheumatologic implications.

Authors:  Zeynel A Sayiner; Uzma Haque; Mohammad U Malik; Ahmet Gurakar
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-05

6.  A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis.

Authors:  Mittermayer Santiago; Murray Baron; Kiyomitsu Miyachi; Marvin J Fritzler; M Abu-Hakima; S Leclercq; M Bell; M Hudson; J-P Mathieu; S Taillefer; N Jones; P Docherty; M Khraishi; J Markland; J Pope; D Robinson; D Smith; E Sutton
Journal:  Clin Rheumatol       Date:  2007-06-15       Impact factor: 2.980

7.  Usefulness of anti-CCP antibodies in patients with hepatitis C virus infection with or without arthritis, rheumatoid factor, or cryoglobulinemia.

Authors:  Feng-Cheng Liu; You-Chen Chao; Tsung-Yun Hou; Hsiang-Cheng Chen; Rong-Yaun Shyu; Tsai-Yuan Hsieh; Chen-Hung Chen; Deh-Ming Chang; Jenn-Haung Lai
Journal:  Clin Rheumatol       Date:  2007-09-18       Impact factor: 2.980

8.  The diagnostic utilities of anti-agalactosyl IgG antibodies, anti-cyclic citrullinated peptide antibodies, and rheumatoid factors in rheumatoid arthritis.

Authors:  Hee Jung Ryu; Fujio Takeuchi; Shoji Kuwata; Yoon Jun Kim; Eun Young Lee; Eun Bong Lee; Yeong Wook Song
Journal:  Rheumatol Int       Date:  2009-12-15       Impact factor: 2.631

9.  Anti-cyclic citrullinated peptide antibodies as a discriminating marker between rheumatoid arthritis and chronic hepatitis C-related polyarthropathy.

Authors:  Wafaa M Ezzat; Hala M Raslan; Azza A Aly; Nahed A Emara; Manal M El Menyawi; Amr Edrees
Journal:  Rheumatol Int       Date:  2009-11-01       Impact factor: 2.631

Review 10.  The role of anti-cyclic cytrullinate antibodies testing in rheumatoid arthritis.

Authors:  Cristiano Alessandri; Roberta Priori; Mariagrazia Modesti; Riccardo Mancini; Guido Valesini
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.